What is the main risk associated with eculizumab therapy in atypical hemolytic uremic syndrome (aHUS)?

Meningococcal meningitis, which occurred in two of 100 patients included in prospective trials. Patients receiving eculizumab should receive specific meningococcal prophylaxis.

Learn more here.